Is NCT01890590 recruiting in Boston, MA?

Yes, NCT01890590 is currently recruiting participants at its Boston, MA location. This renal cell carcinoma clinical trial is actively enrolling qualified participants.

How do I join the renal cell carcinoma clinical trial in Boston?

To join this clinical trial in Boston, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Boston clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Renal Cell Carcinoma Clinical Trial in Boston, MA

About This Renal Cell Carcinoma Study in Boston

CyberKnife Based Radiosurgery is a way to deliver large doses of radiation very accurately to a tumor. The ability of this technology to minimize radiation dose to organs adjacent to the target tumor allows a high dose to be delivered to the tumor, thus potentially increasing the efficacy of radiation treatment. Currently, radiosurgery is commonly used for brain metastases, Stage I lung cancer, spine tumors, and localized prostate cancer. The purpose of this protocol is to evaluate the role of Radiosurgery for the treatment of clinically localized primary renal cell carcinoma.

Sponsor: Beth Israel Deaconess Medical Center

Who Can Participate

Inclusion Criteria

Participants must meet the following criteria on screening examination to be eligible to participate in the study:

Participants must have histologically or radiological evidence of Stage I (T1N0M0) renal cell carcinoma with a size no larger than 8 cm in greatest dimension measured by MRI or CT Scan

At least one (usually up to 3) gold fiducial placed in or around tumor, can be performed on the same day - after signing research informed consent.

No irreversible coagulopathies

Age ≥ 18 years old because no dosing or adverse event data are currently available on the use of Cyberknife Radiosurgery radiation in participants \<18 years of age, children are excluded from this study but will be eligible for future pediatric Phase II trials.

ECOG Performance Status ≤2 (Appendix A).

At least 12 month life expectancy

Ability to have CT and/or MRI imaging with or without contrast and must be performed within 120 days prior to registration.

No other cancer in previous 2 years with the exception of non-invasive skin cancers

All subjects meeting eligibility criteria irrespective of gender, minority or other underrepresented status will be eligible for enrollment into the study.

The effects of Cyberknife Radiosurgery on the developing human fetus are unknown. For this reason and because Radiation is known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

Ability to understand and the willingness to sign a written informed consent document and study specific consent form prior to study entry.

Labs: Serum Creatinin \<3 mg/dl, Urinalysis, INR \<2, PTT \<70 sec, AST, ALT ≤2.5x ULN, Abnormalities on urinalysis (i.e. proteinuria) will not exclude patients from participation on study.

Exclusion Criteria

Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study.

Irreversible coagulopathies that preclude fiducial placement

Prior upper abdominal external beam irradiation

Prior history of invasive malignancy within the last 2 years

Inability to deliver target dose with CyberKnife due to inability to image fiducials

Inability to deliver target dose with CyberKnife due to normal tissue dose constraints

Inability to have contrast CT or MRI to help define tumor volume for radiation planning

Decreased platelet count and / or anticoagulation parameters that would preclude transcutaneous placement of fiducials

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT01890590) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Renal Cell Carcinoma Treatment Options in Boston, MA

If you're searching for renal cell carcinoma treatment options in Boston, MA, this clinical trial (NCT01890590) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced renal cell carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all renal cell carcinoma clinical trials near you to find additional studies recruiting in your area.

Renal Cell Carcinoma Clinical Trial in Boston, MA

Expert Care in Boston

IRB Approved

No-Cost Care

Apply for This Boston Location

Why Participate?

Simple Process